Abbott's Xience V drug-eluting coronary stent superior to Taxus in trial

By E. Janene Geiss

Philadelphia, Sept. 5 - Abbott said Tuesday that positive six-month results of its Spirit II clinical trial of the Xience V everolimus eluting coronary stent system demonstrated superiority compared to the Taxus paclitaxel-eluting coronary stent system with respect to the study's primary endpoint, which was angiographic in-stent late loss at six months.

Late loss is a measure of the change in the vessel diameter between the time immediately following stent placement and at six months, according to a news release from the Abbott Park, Ill., pharmaceutical company.

Secondary endpoints also demonstrated positive results for the stent system, including a statistically significant reduction in percent diameter stenosis from 21% for Taxus to 16% for Xience V.

The results were presented Tuesday at the World Congress of Cardiology conference in Barcelona.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.